ENGLEWOOD, Colo., Dec. 4, 2019 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled “Evaluating the Efficacy and...
NEW YORK, Dec. 4, 2019 Eolas Therapeutics Inc. today announced the initiation of a Phase I study of AZD4041 for treating tobacco use and dependence. The study will investigate safety and pharmacokinetics (PK) of AZD4041 in healthy volunteers. AZD4041 is a central...
London, UK, 4 December 2019: The first UK clinical trial site for the treatment of diabetic patients with chronic limb-threatening ischemia (CLI) using a novel patient-specific regenerative therapy has opened for patient recruitment at the University Hospital of Wales...
PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) Phase II Part I trial of ABV-1505 to be conducted at the University of California, San Francisco...
LA JOLLA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional analyses of...
First indication of human safety and PK profiles for SPR720 supports advancement of program to a Phase 2a proof-of-concept clinical trial in patients planned to initiate in the second half of 2020 CAMBRIDGE, MA, USA I December 04, 2019 I Spero Therapeutics, Inc....
Email
Text